Autophagy-Based Therapy for Hepatocellular Carcinoma: From Standard Treatments to Combination Therapy, Oncolytic Virotherapy, and Targeted Nanomedicines Publisher Pubmed



Rahdan F¹ ; Abedi F² ; Dianatmoghadam H^{3, 4} ; Sani MZ⁵ ; Taghizadeh M⁶ ; Alizadeh E¹ Show Affiliations
Source: Clinical and Experimental Medicine Published:2025

Abstract

Human hepatocellular carcinoma (HCC) has been identified as a significant cause of mortality worldwide. In recent years, extensive research has been conducted to understand the underlying mechanisms of autophagy in the pathogenesis of the disease, with the aim of developing novel therapeutic agents. Targeting autophagy with conventional therapies in invasive HCC has opened up new opportunities for treatment. However, the emergence of resistance and the immunosuppressive tumor environment highlight the need for combination therapy or specific targeting, as well as an efficient drug delivery system to ensure targeted tumor areas receive sufficient doses without affecting normal cells or tissues. In this review, we discuss the findings of several studies that have explored autophagy as a potential therapeutic approach in HCC. We also outline the potential and limitations of standard therapies for autophagy modulation in HCC treatment. Additionally, we discuss how different combination therapies, nano-targeted strategies, and oncolytic virotherapy could enhance autophagy-based HCC treatment in future research. © The Author(s) 2024.